New combo aims to wipe out returning nose cancer with chemo, immunotherapy, and surgery
NCT ID NCT07129772
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether giving pembrolizumab (an immunotherapy) plus chemotherapy before surgery, followed by maintenance pembrolizumab, can improve outcomes for people with locally recurrent nasopharyngeal carcinoma. About 53 participants will receive up to 6 cycles of the drug combo, then undergo minimally invasive surgery to remove any remaining tumor, followed by a year of pembrolizumab. The main goal is to see how many patients have no cancer cells left in their surgical samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab, gemcitabine, cisplatin
What this could lead to
If successful, this approach could offer a chance to remove recurrent tumors completely and reduce the need for long-term immunotherapy.
What could go wrong
This is a small, early-phase trial with only 53 people, so results may not apply widely. There are risks from chemotherapy, surgery, and immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Queen Mary Hospital
Hong Kong, Hong Kong